Mereo BioPharma Group plc (MREO)
Develops medicines for rare diseases like brittle bone disease and genetic lung conditions.
$0.31+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-81.4%
The outlook
MREO is trading near its 52-week lows with mixed momentum versus its moving averages. Analyst consensus leans bullish, with an average price target suggesting substantial upside, though the stock has shown limited recent price movement. The overall sentiment is neutral despite the optimistic analyst views.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 6 analysts
Price trendMixed vs its moving averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +454% vs current price
Analyst price target
~12-month · 6 analysts$1.71average target+454.1% vs now
Now $0.31
Low $0.49High $2.95
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$49.4M
52-wk high
$2.37
52-wk low
$0.20
50-day avg
$0.31
200-day avg
$0.81
Trailing P/E
—